Spero Therapeutics, Inc. (SPRO) research
Spero Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.19
- As of
Spero Therapeutics, Inc. (SPRO): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-28.
As of . Source: SEC EDGAR filings for SPRO. Method and limitations.
Share the SPRO intelligence card
See the full SPRO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SPRO on one page. Preview it with sample data, then open it live with a free account.
Preview the SPRO dossierActive signals for SPRO
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +75% to SPRO (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 57% of SPRO (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 7.7%, EPS $-0.16 vs $-0.1734 estimate
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +138% to SPRO (2026Q1)
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 49.0% - EPS $-0.13 vs $-0.255 estimate
FREE, NO ACCOUNT
Every signal on SPRO, as it fires
You are seeing 5 of 10 signals recorded on SPRO since 2026-05-30.
The five above landed across 4 days. The other 5 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SPRO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 84833T103 · 2026Q2 | $2.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 84833T103 · 2026Q2 | $846K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 84833T103 · 2026Q2 | $231K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 84833T103 · 2026Q2 | $43K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SPRO
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SPRO against its peers
SPRO's operating margin of 50.2% ranks in the 94th percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | SPRO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 12.6M USD | 1.1M USD | 54 | 11 |
| Operating margin | 50.2% | -231.6% | 94 | 8 |
| Net margin | 68.1% | -200.9% | 94 | 8 |
| Return on equity | 14.5% | -92.5% | 97 | 18 |
| P / E | 7.9x | n/a | n/a | 0 |
Peers (21): RNXT, ALDX, CSBR, CING, GOSS, CNTB, KLRS, MAIA, HRTX, FBIO, PMVP, XBIT, TENX, GUTS, ATHE, RNTX, OSTX, GANX, INKT, HYPD, VRCA. Left out: APLM (period gap), OKYO (period gap), BSEM (no annual filing), HYFT (period gap). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (SPRO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SPRO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SPROand get the insider, 13F, options, and confluence read in one view.